/PRNewswire/ Tirzepatide (5 mg, 10 mg, 15 mg) achieved superior weight loss compared to placebo at 72 weeks of treatment in topline results from Eli Lilly.
/PRNewswire/ Tirzepatide (5 mg, 10 mg, 15 mg) achieved superior weight loss compared to placebo at 72 weeks of treatment in topline results from Eli Lilly.
Share this article
Share this article
INDIANAPOLIS, May 20, 2021 /PRNewswire/ Tirzepatide led to superior A1C and body weight reductions from baseline across all three doses in adults with type 2 diabetes who have increased cardiovascular (CV) risk compared to titrated insulin glargine in topline results from Eli Lilly and Company s (NYSE: LLY) SURPASS-4 clinical trial. For the efficacy estimand
i, the highest dose of tirzepatide led to an A1C reduction of 2.58 percent and reduced body weight by 11.7 kg (25.8 lb., 13.0 percent) compared to results for those treated with insulin glargine (A1C reduction of 1.44 percent and weight gain of 1.9 kg [4.2 lb., 2.2 percent]) at 52 weeks.
Tirzepatide achieved superior A1C and body weight reductions across all three doses compared to injectable semaglutide in adults with type 2 diabetes
Trial participants taking the highest dose of tirzepatide (15 mg) achieved an A1C reduction of 2.46 percent and weight loss of 12.4 kg (27.3 lb., 13.1 percent), double the weight reduction compared to those taking semaglutide 1 mg
At the lowest dose of tirzepatide (5 mg), participants achieved A1C and body weight reductions of 2.09 percent and 7.8 kg (17.2 lb., 8.5 percent), significantly greater than semaglutide
News provided by
Share this article
Share this article
INDIANAPOLIS, March 4, 2021 /PRNewswire/ Tirzepatide led to superior A1C and body weight reductions from baseline across all three doses compared to injectable semaglutide 1 mg in adults with type 2 diabetes in Eli Lilly and Company s (NYSE: LLY) 40-week SURPASS-2 clinical trial. In topline results from the largest SURPASS trial to date, using the efficacy estimand